Advancing COVID-19 Treatments

Efficiently launching medical products to combat the current and future outbreaks of COVID-19 requires supporting the Food and Drug Administration's (FDA) work with manufacturers that have high potential to develop and deliver needed diagnostics, therapeutics, and prophylactics, stated former FDA Commissioners Scott Gottlieb, MD and Mark McClellan, MD, PhD, in working paper issued today by the Duke-Margolis Center for Health Policy.